AR040629A1 - Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivados - Google Patents
Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivadosInfo
- Publication number
- AR040629A1 AR040629A1 AR20020104169A ARP020104169A AR040629A1 AR 040629 A1 AR040629 A1 AR 040629A1 AR 20020104169 A AR20020104169 A AR 20020104169A AR P020104169 A ARP020104169 A AR P020104169A AR 040629 A1 AR040629 A1 AR 040629A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- formula
- procedure
- preparation
- compounds
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01125455 | 2001-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040629A1 true AR040629A1 (es) | 2005-04-13 |
Family
ID=8179075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20020104169A AR040629A1 (es) | 2001-11-05 | 2002-11-01 | Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivados |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7141572B2 (enExample) |
| EP (1) | EP1441730B1 (enExample) |
| JP (1) | JP5116940B2 (enExample) |
| KR (1) | KR100898894B1 (enExample) |
| CN (1) | CN1585641A (enExample) |
| AR (1) | AR040629A1 (enExample) |
| AT (1) | ATE335486T1 (enExample) |
| AU (1) | AU2002363368B2 (enExample) |
| BR (1) | BR0213683A (enExample) |
| CA (1) | CA2465746C (enExample) |
| DE (1) | DE60213841T2 (enExample) |
| ES (1) | ES2268157T3 (enExample) |
| HU (1) | HUP0401747A3 (enExample) |
| MX (1) | MXPA04004263A (enExample) |
| MY (1) | MY129491A (enExample) |
| PL (1) | PL369738A1 (enExample) |
| RU (1) | RU2302412C2 (enExample) |
| WO (1) | WO2003039548A1 (enExample) |
| ZA (1) | ZA200404387B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
| WO2004067006A1 (en) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| JPWO2004087641A1 (ja) * | 2003-03-31 | 2006-06-29 | 第一製薬株式会社 | ヒドラゾン誘導体 |
| PE20060272A1 (es) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| RS52944B (sr) * | 2005-04-19 | 2014-02-28 | Takeda Gmbh | Roflumilast za lečenje pulmonarne hipertenzije |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| CA2648036C (en) | 2006-03-31 | 2012-05-22 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| JP6063123B2 (ja) | 2008-11-15 | 2017-01-18 | メリンタ セラピューティクス、インク | 抗菌性組成物 |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| US8440655B2 (en) * | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| ES2773543T3 (es) * | 2013-03-06 | 2020-07-13 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4 |
| WO2015054359A1 (en) * | 2013-10-08 | 2015-04-16 | Ebadi Mark A | Methods and compositions for symptomatic reflief of the common cold |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| AU2015298378B2 (en) | 2014-08-06 | 2018-08-02 | Pfizer Inc. | Imidazopyridazine compounds |
| US10500178B2 (en) | 2015-03-13 | 2019-12-10 | The Board Of Trustees Of The Leland Stanford Junior University | LTB4 inhibition to prevent and treat human lymphedema |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| DE19632549A1 (de) * | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE19826841A1 (de) * | 1998-06-16 | 1999-12-23 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE19850701A1 (de) * | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
| DE19932315A1 (de) | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzoylpyridazine |
-
2002
- 2002-10-10 CA CA2465746A patent/CA2465746C/en not_active Expired - Fee Related
- 2002-10-10 KR KR1020047006820A patent/KR100898894B1/ko not_active Expired - Fee Related
- 2002-10-10 DE DE60213841T patent/DE60213841T2/de not_active Expired - Lifetime
- 2002-10-10 AT AT02802625T patent/ATE335486T1/de not_active IP Right Cessation
- 2002-10-10 BR BR0213683-0A patent/BR0213683A/pt not_active IP Right Cessation
- 2002-10-10 WO PCT/EP2002/011351 patent/WO2003039548A1/en not_active Ceased
- 2002-10-10 HU HU0401747A patent/HUP0401747A3/hu unknown
- 2002-10-10 ES ES02802625T patent/ES2268157T3/es not_active Expired - Lifetime
- 2002-10-10 AU AU2002363368A patent/AU2002363368B2/en not_active Ceased
- 2002-10-10 JP JP2003541839A patent/JP5116940B2/ja not_active Expired - Fee Related
- 2002-10-10 RU RU2004117171/04A patent/RU2302412C2/ru not_active IP Right Cessation
- 2002-10-10 US US10/494,631 patent/US7141572B2/en not_active Expired - Fee Related
- 2002-10-10 PL PL02369738A patent/PL369738A1/xx not_active Application Discontinuation
- 2002-10-10 CN CNA028222164A patent/CN1585641A/zh active Pending
- 2002-10-10 MX MXPA04004263A patent/MXPA04004263A/es active IP Right Grant
- 2002-10-10 EP EP02802625A patent/EP1441730B1/en not_active Expired - Lifetime
- 2002-11-01 AR AR20020104169A patent/AR040629A1/es unknown
- 2002-11-01 MY MYPI20024107A patent/MY129491A/en unknown
-
2004
- 2004-06-03 ZA ZA200404387A patent/ZA200404387B/en unknown
-
2006
- 2006-08-02 US US11/497,235 patent/US7544684B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2465746A1 (en) | 2003-05-15 |
| RU2004117171A (ru) | 2006-01-10 |
| US7141572B2 (en) | 2006-11-28 |
| CN1585641A (zh) | 2005-02-23 |
| CA2465746C (en) | 2011-09-06 |
| ZA200404387B (en) | 2006-02-22 |
| AU2002363368B2 (en) | 2007-12-13 |
| US20060270676A1 (en) | 2006-11-30 |
| KR20050035177A (ko) | 2005-04-15 |
| HUP0401747A2 (hu) | 2005-01-28 |
| ES2268157T3 (es) | 2007-03-16 |
| PL369738A1 (en) | 2005-05-02 |
| BR0213683A (pt) | 2004-10-26 |
| RU2302412C2 (ru) | 2007-07-10 |
| WO2003039548A1 (en) | 2003-05-15 |
| JP5116940B2 (ja) | 2013-01-09 |
| JP2005511595A (ja) | 2005-04-28 |
| MY129491A (en) | 2007-04-30 |
| EP1441730B1 (en) | 2006-08-09 |
| DE60213841T2 (de) | 2007-02-15 |
| US20040261190A1 (en) | 2004-12-30 |
| EP1441730A1 (en) | 2004-08-04 |
| US7544684B2 (en) | 2009-06-09 |
| HUP0401747A3 (en) | 2005-06-28 |
| MXPA04004263A (es) | 2004-07-08 |
| ATE335486T1 (de) | 2006-09-15 |
| KR100898894B1 (ko) | 2009-05-21 |
| AU2002363368B9 (en) | 2003-05-19 |
| DE60213841D1 (de) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040629A1 (es) | Derivados de hidrazono-malonitrilo, los medicamentos que los contienen, uso para la preparacion de un medicamento, un conjunto de elementos (kit) que los comprende, un procedimiento para la preparacion, los intermediarios utiles en dicho procedimiento, y las combinaciones de uno de dichos derivados | |
| AR037972A1 (es) | Pirrolopirimidinas | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| UY28374A1 (es) | Agentes terapéuticos | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| UY28369A1 (es) | Agentes terapéuticos | |
| UY28752A1 (es) | Agentes terapeuticos | |
| AR067396A1 (es) | Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende | |
| SE0104334D0 (sv) | Therapeutic agents | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| UY28376A1 (es) | Agentes terapéuticos | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| JP6454335B2 (ja) | カテプシンシステインプロテアーゼ阻害剤 | |
| AR030007A1 (es) | Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento | |
| UY28377A1 (es) | Agentes terapeuticos | |
| AR015446A1 (es) | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| AR041678A1 (es) | Formas cristalinas de clorhidrato de donepezil | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| AR035685A1 (es) | Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac | |
| AR032622A1 (es) | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |